News and Trends 1 Jun 2023 Swiss researchers develop new class of antibiotics to fight resistant bacteria Health professionals are in urgent need of new antibiotics to tackle resistant bacteria. Researchers at the University of Zurich (UZH), in Switzerland, and the company Spexis, have now modified the chemical structure of naturally occurring peptides to develop antimicrobial molecules that bind to novel targets in the bacteria’s metabolism. Each year, more than five million […] June 1, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 1 Jun 2023 Sanofi drug reduces disease activity in relapsing MS New data, being presented in a late-breaking session at the 2023 Consortium of Multiple Sclerosis Centers (CMSC) annual meeting, demonstrate that frexalimab, Sanofi’s novel second-generation investigational anti-CD40L antibody, with a unique mechanism of action, significantly reduced disease activity in a phase 2 trial of patients with relapsing multiple sclerosis (MS). Following 12 weeks of therapy, […] June 1, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 1 Jun 2023 ElevateBio raises $401M for cell and gene therapies ElevateBio, LLC (ElevateBio), a technology-driven company focused on cell and gene therapies, has closed its $401 million Series D financing. “We have made significant strides in scaling our technologies and end-to-end capabilities in our pursuit to become the world’s most indispensable cell and gene therapy technology company. We are thrilled to welcome Khalil to our […] June 1, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 1 Jun 2023 Fighting obesity with gene therapy Scientists from the University of Barcelona in Spain and the Physiopathology of Obesity and Nutrition Networking Biomedical Research Centre (CIBERobn) have designed a strategy to fight obesity and diabetes in mice through ex vivo gene therapy. The technique consists of implanting cells that have been manipulated and transformed in order to treat a disease. This […] June 1, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 1 Jun 2023 Lonza boosts ADC portfolio with Synaffix acquisition Lonza has acquired Synaffix B.V., a biotech company focused on commercializing its clinical-stage technology platform for the development of antibody drug conjugates (ADCs). While ADCs offer widespread and targeted treatment potential against cancer, they present a range of complex development and manufacturing challenges. Supported by a team of scientific experts, the Synaffix technology platform, which […] June 1, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 1 Jun 2023 SNIPR Biome sees positive results for first-in-human CRISPR microbial gene therapy CRISPR-based microbial gene therapy company SNIPR Biome ApS has announced positive interim clinical results from its phase 1 clinical trial with SNIPR001. SNIPR Biome’s SNIPR001 is the first CRISPR-armed phage therapeutic developed to specifically target and remove E. coli, including antibiotic-resistant strains, from the human gastrointestinal tract. The work was supported by CARB-X, a global […] June 1, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
In Depth 31 May 2023 Biotechnology in developing countries: challenges and opportunities Choosing to grow their biotechnology sectors can offer developing countries vast opportunities, helping them to grow economically, providing new jobs, and supporting sustainable development, public health, and environmental protection. In recent times, significant growth has been achieved by the developing world in biotechnology fields, mainly tied to food production, healthcare, and other dimensions of human […] May 31, 2023 - 7 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
News and Trends 31 May 2023 Artificial intelligence combats lethal superbug, new antibiotic discovered A new antibiotic called abaucin that can kill a deadly, drug-resistant pathogen has been discovered with the help of artificial intelligence (AI). Research published in Nature Chemical Biology showed that AI was able to rapidly screen 7,500 molecules that were found to inhibit the growth of the superbug Acinetobacter baumannii, a task that would be […] May 31, 2023 - 3 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 30 May 2023 New study reveals Alzheimer’s inflammation protection A possible explanation has been found in a study for why apoE4, the most significant genetic risk factor associated with Alzheimer’s disease, fails to protect the brain from inflammation.Alzheimer’s disease is characterized by the accumulation of plaques of the amyloid-β protein, chronic inflammation and impaired neuronal function in the brain. The most significant genetic risk […] May 30, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 30 May 2023 Pancreatic cancer microbiome discovery holds treatment hope iNtRON Biotechnology has announced the identification of prophage and (non-) ORF-jamphage from the microbiome frequently observed in long-term pancreatic cancer survivors. The company said the ‘significant identification’ was achieved as part of its ongoing PHAGERIARUS development project conducted by the new drug part of the company. The PHAGERIARUS development project is focused on acquiring bacteriophage-derived […] May 30, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 30 May 2023 Potential targets against natural killer/T-cell lymphoma found A team of researchers from the Cancer Science Institute of Singapore (CSI Singapore) at the National University of Singapore (NUS) has discovered that a transcription factor, TOX2, was aberrantly increased in patients with natural killer/T-cell lymphoma (NKTL). The increased TOX2 level leads to the growth and spread of NKTL, as well as the overproduction of […] May 30, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 30 May 2023 Researchers identify gene expression signature to predict progression of type 1 diabetes Researchers from Turku Bioscience Centre and InFLAMES Flagship at the University of Turku in Finland, have identified a gene expression signature that can predict the progression of type 1 diabetes.The study, led by Laura Elo and Riitta Lahesmaa, aimed to identify transcriptional changes associated with disease progression in patients with recent-onset type 1 diabetes. The […] May 30, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email